News
The CFDA's Steven Kolb, the AAFA's Stephen Lamar and Condé Nast's chief content officer Anna Wintour traveled to Washington, ...
NurExone expects to initiate a Phase 1/2a clinical trial in 2026 (" 2026 SCI Trial ”) marking a major milestone in the advancement of regenerative therapies for central nervous system injuries.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback